Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 | Zendy

Yuto Unoh | Zendy; Shota Uehara | Zendy; Kenji Nakahara | Zendy; Haruaki Nobori | Zendy; Yukiko Yamatsu | Zendy; Shiho Yamamoto | Zendy; Yuki Maruyama | Zendy; Yoshiyuki Taoda | Zendy; Koji Kasamatsu | Zendy; Takahiro Suto | Zendy; Kensuke Kouki | Zendy; Atsufumi Nakahashi | Zendy; Sho Kawashima | Zendy; Takao Sanaki | Zendy; Shinsuke Toba | Zendy; Kentaro Uemura | Zendy; Tohru Mizutare | Zendy; Shigeru Ando | Zendy; Michihito Sasaki | Zendy; Yasuko Orba | Zendy; Hirofumi Sawa | Zendy; Akihiko Sato | Zendy; Takafumi Sato | Zendy; Teruhisa Kato | Zendy; Yuki Tachibana | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Author(s) -

Yuto Unoh,

Shota Uehara,

Kenji Nakahara,

Haruaki Nobori,

Yukiko Yamatsu,

Shiho Yamamoto,

Yuki Maruyama,

Yoshiyuki Taoda,

Koji Kasamatsu,

Takahiro Suto,

Kensuke Kouki,

Atsufumi Nakahashi,

Sho Kawashima,

Takao Sanaki,

Shinsuke Toba,

Kentaro Uemura,

Tohru Mizutare,

Shigeru Ando,

Michihito Sasaki,

Yasuko Orba,

Hirofumi Sawa,

Akihiko Sato,

Takafumi Sato,

Teruhisa Kato,

Yuki Tachibana

Publication year - 2022

Publication title -

journal of medicinal chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.01

H-Index - 261

eISSN - 1520-4804

pISSN - 0022-2623

DOI - 10.1021/acs.jmedchem.2c00117

Subject(s) - pharmacology , protease inhibitor (pharmacology) , pharmacokinetics , dosing , covid-19 , in vivo , virtual screening , virology , drug , coronavirus , ex vivo , chemistry , pandemic , drug discovery , antiviral drug , in vitro , medicine , virus , viral load , disease , biology , infectious disease (medical specialty) , biochemistry , microbiology and biotechnology , antiretroviral therapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research